Avalo Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Avalo Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2015 to 2023.
  • Avalo Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was -$14K, a 275% decline year-over-year.
  • Avalo Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was -$9K, a 128% decline year-over-year.
  • Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $14K, a 50% decline from 2022.
  • Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $28K.
  • Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was -$196K, a 93% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.